Typhoid conjugate vaccine - Bharat Biotech

Drug Profile

Typhoid conjugate vaccine - Bharat Biotech

Alternative Names: Typbar-TCV; Typhoid conjugate vaccine (Typbar-TCV) - Bharat Biotech; Typhoid Vi capsular polysaccharide tetanus toxoid protein conjugate vaccine (Typbar-TCV) - BBIL; Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV) - Bharat Biotech; Typhoid Vi polysaccharide-TT conjugate vaccine - Bharat Biotech

Latest Information Update: 17 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bharat Biotech
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Typhoid

Most Recent Events

  • 15 Apr 2014 Bharat Biotech initiates enrolment in a phase IV trial for Typhoid in India (CTRI2014-04-004532)
  • 26 Aug 2013 Launched for Typhoid (prevention) in India (IM); first launch of Typbar-TCV™
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top